Enterprise Therapeutics Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$33.1M
- Investors
-
8
Enterprise Therapeutics General Information
Description
Operator of a drug discovery and development firm intended to develop novel therapies for the treatment of respiratory diseases. The company specializes in developing and discovering new disease-modifying therapies for diseases such as cystic fibrosis, asthma, and COPD, enabling patients to reduce the frequency of lung infections and improve their quality of life.
Contact Information
Website
www.enterprisetherapeutics.comCorporate Office
- Sussex Innovation Centre
- University of Sussex, Science Park Square, Falmer
- Brighton BN1 9SB
- England, United Kingdom
Corporate Office
- Sussex Innovation Centre
- University of Sussex, Science Park Square, Falmer
- Brighton BN1 9SB
- England, United Kingdom
Enterprise Therapeutics Timeline
Enterprise Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC (Series B) | 26-Jan-2024 | $33.1M | Completed | Generating Revenue | ||
| 8. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 7. Later Stage VC | 09-Mar-2022 | Completed | Generating Revenue | |||
| 6. Secondary Transaction - Private | 06-Oct-2020 | Completed | Generating Revenue | |||
| 5. Grant | 15-Oct-2019 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series B) | 06-Apr-2018 | Completed | Generating Revenue | |||
| 3. Early Stage VC | 10-Nov-2016 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 20-May-2015 | $12.9M | $12.9M | Completed | Startup | |
| 1. University Spin-Out | 02-May-2014 | Completed | Startup |
Enterprise Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Enterprise Therapeutics Comparisons
Industry
Financing
Details
Enterprise Therapeutics Competitors (30)
One of Enterprise Therapeutics’s 30 competitors is Vasa Therapeutics, a Venture Capital-Backed company based in Encinitas, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Vasa Therapeutics | Venture Capital-Backed | Encinitas, CA | ||||
| Aqualung Therapeutics | Venture Capital-Backed | Tucson, AZ | ||||
| Verve Therapeutics | Formerly VC-backed | Boston, MA | ||||
| hVIVO | Formerly VC-backed | London, United Kingdom | ||||
| Windtree Therapeutics | Corporate Backed or Acquired | Warrington, PA |
Enterprise Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Enterprise Therapeutics Patents
Enterprise Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202406247-D0 | Compounds and pharmaceutical compositions | Pending | 03-May-2024 | ||
| GB-202405298-D0 | Compounds | Pending | 15-Apr-2024 | ||
| GB-202305328-D0 | Compounds | Inactive | 12-Apr-2023 | ||
| GB-202205261-D0 | Compounds | Inactive | 11-Apr-2022 | ||
| GB-202005739-D0 | Compounds | Inactive | 20-Apr-2020 |
Enterprise Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Enterprise Therapeutics Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Panakes Partners | Venture Capital | Minority | ||
| Roche | Corporation | Minority | ||
| Cystic Fibrosis Foundation | Limited Partner | |||
| Forbion | Venture Capital | Minority | ||
| IP Group | Venture Capital | Minority |
Enterprise Therapeutics FAQs
-
When was Enterprise Therapeutics founded?
Enterprise Therapeutics was founded in 2014.
-
Where is Enterprise Therapeutics headquartered?
Enterprise Therapeutics is headquartered in Brighton, United Kingdom.
-
What is the size of Enterprise Therapeutics?
Enterprise Therapeutics has 10 total employees.
-
What industry is Enterprise Therapeutics in?
Enterprise Therapeutics’s primary industry is Drug Discovery.
-
Is Enterprise Therapeutics a private or public company?
Enterprise Therapeutics is a Private company.
-
What is Enterprise Therapeutics’s current revenue?
The current revenue for Enterprise Therapeutics is .
-
How much funding has Enterprise Therapeutics raised over time?
Enterprise Therapeutics has raised $98.6M.
-
Who are Enterprise Therapeutics’s investors?
Panakes Partners, Roche, Cystic Fibrosis Foundation, Forbion, and IP Group are 5 of 8 investors who have invested in Enterprise Therapeutics.
-
Who are Enterprise Therapeutics’s competitors?
Vasa Therapeutics, Aqualung Therapeutics, Verve Therapeutics, hVIVO, and Windtree Therapeutics are some of the 30 competitors of Enterprise Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
